약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 9.

Table. 9.

Signal detection of tocilizumab

PRR ROR IC signal
Skin and appendages disorders 1.70 1.94 0.34 Y
Rash 3.09 3.30 0.83 Y
Pruritus 2.26 2.37 0.46 Y
Urticaria 5.25 5.45 1.13 Y
Rash erythematous 5.15 5.21 0.64 Y
Alopecia 0.76 0.75 -1.43
Body as a whole-general disorders 1.13 1.15 -0.25
Anaphylactic reaction 50.99 52.49 1.99 Y
Chest pain 5.15 5.26 0.93 Y
Fever 1.22 1.23 -0.67
Rigors 4.12 4.15 0.36 Y
Oedema peripheral 1.64 1.64 -0.61
Back pain 5.56 5.60 0.45 Y
Respiratory system disorders 1.32 1.36 -0.11
Dyspnoea 2.94 3.01 0.51 Y
Pharyngitis 2.78 2.81 0.18 Y
Pneumonia 0.46 0.45 -1.97
Coughing 6.62 6.70 0.81 Y
Upper respiratory tract infection 0.90 0.90 -1.21
Liver and biliary system disorders 1.79 1.88 0.24 Y
Hepatic enzymes increased 5.33 5.61 1.24 Y
SGPT increased 1.24 1.24 -0.84
SGOT increased 1.00 1.00 -1.08
White cell and RES* disorders 1.59 1.64 0.04 Y
Leucopenia 6.42 6.69 1.31 Y
Granulocytopenia 0.59 0.58 -1.59
Yakhak Hoeji 2022;66:49-57 https://doi.org/10.17480/psk.2022.66.2.49
© 2022 Yakhak Hoeji